MARC details
000 -LEADER |
fixed length control field |
04806nam a22008177a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
130807s20132013 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
1079-5642 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
23175674 |
245 ## - TITLE STATEMENT |
Title |
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. |
251 ## - Source |
Source |
Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb. |
252 ## - Abbreviated Source |
Abbreviated source |
Arterioscler Thromb Vasc Biol. 33(2):393-9, 2013 Feb. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2013 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2013 |
266 ## - Date added to catalog |
Date added to catalog |
2013-09-17 |
501 ## - WITH NOTE |
Local holdings |
Available online from MWHC library: 1995 - present |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSIONS: Pioglitazone slowed progression of CIMT, independent of improvement in hyperglycemia, insulin resistance, dyslipidemia, and systemic inflammation in prediabetes. These results suggest a possible direct vascular benefit of pioglitazone. |
520 ## - SUMMARY, ETC. |
Abstract |
METHODS AND RESULTS: CIMT was measured in 382 participants at the beginning and up to 3 additional times during follow-up of the Actos Now for Prevention of Diabetes trial. During an average follow-up of 2.3 years, the mean unadjusted annual rate of CIMT progression was significantly (P=0.01) lower with pioglitazone treatment (4.76x10(-3) mm/year; 95% CI: 2.39x10(-3)-7.14x10(-3) mm/year) compared with placebo (9.69x10(-3) mm/year; 95% CI: 7.24x10(-3)-12.15x10(-3) mm/year). High-density lipoprotein cholesterol, fasting and 2-hour glucose, HbA(1c), fasting insulin, Matsuda insulin sensitivity index, adiponectin, and plasminogen activator inhibitor-1 levels improved significantly with pioglitazone treatment compared with placebo (P<0.001). However, the effect of pioglitazone on CIMT progression was not attenuated by multiple methods of adjustment for traditional, metabolic, and inflammatory risk factors and concomitant medications, and was independent of changes in risk factors during pioglitazone treatment. |
520 ## - SUMMARY, ETC. |
Abstract |
OBJECTIVE: To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Carotid Artery Diseases/pc [Prevention & Control] |
9 (RLIN) |
607 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Diabetes Mellitus, Type 2/pc [Prevention & Control] |
9 (RLIN) |
608 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Hypoglycemic Agents/tu [Therapeutic Use] |
9 (RLIN) |
261 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Prediabetic State/dt [Drug Therapy] |
9 (RLIN) |
609 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Thiazolidinediones/tu [Therapeutic Use] |
9 (RLIN) |
610 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Adiponectin/bl [Blood] |
9 (RLIN) |
611 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Adult |
9 (RLIN) |
13 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Aged |
9 (RLIN) |
2 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Biological Markers/bl [Blood] |
9 (RLIN) |
399 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Blood Glucose/de [Drug Effects] |
9 (RLIN) |
612 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Blood Glucose/me [Metabolism] |
9 (RLIN) |
613 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carotid Artery Diseases/bl [Blood] |
9 (RLIN) |
614 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carotid Artery Diseases/di [Diagnosis] |
9 (RLIN) |
615 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carotid Artery Diseases/et [Etiology] |
9 (RLIN) |
616 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carotid Intima-Media Thickness |
9 (RLIN) |
617 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Chi-Square Distribution |
9 (RLIN) |
39 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cholesterol, HDL/bl [Blood] |
9 (RLIN) |
618 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Diabetes Mellitus, Type 2/bl [Blood] |
9 (RLIN) |
619 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Diabetes Mellitus, Type 2/di [Diagnosis] |
9 (RLIN) |
620 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Diabetes Mellitus, Type 2/et [Etiology] |
9 (RLIN) |
621 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Disease Progression |
9 (RLIN) |
468 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Double-Blind Method |
9 (RLIN) |
622 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Female |
9 (RLIN) |
7 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Hemoglobin A, Glycosylated/me [Metabolism] |
9 (RLIN) |
623 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
9 (RLIN) |
11 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Insulin/bl [Blood] |
9 (RLIN) |
624 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Linear Models |
9 (RLIN) |
487 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Male |
9 (RLIN) |
14 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Middle Aged |
9 (RLIN) |
15 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Multivariate Analysis |
9 (RLIN) |
302 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Plasminogen Activator Inhibitor 1/bl [Blood] |
9 (RLIN) |
625 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Prediabetic State/bl [Blood] |
9 (RLIN) |
626 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Prediabetic State/co [Complications] |
9 (RLIN) |
627 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Prediabetic State/di [Diagnosis] |
9 (RLIN) |
628 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Prospective Studies |
9 (RLIN) |
177 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Risk Assessment |
9 (RLIN) |
514 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Risk Factors |
9 (RLIN) |
311 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Time Factors |
9 (RLIN) |
48 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Treatment Outcome |
9 (RLIN) |
18 |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
United States |
9 (RLIN) |
82 |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Health Research Institute |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Multicenter Study |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Randomized Controlled Trial |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Research Support, Non-U.S. Gov't |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Research Support, U.S. Gov't, Non-P.H.S. |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Ratner, Robert E |
9 (RLIN) |
606 |
790 ## - Authors |
All authors |
Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="http://dx.doi.org/10.1161/ATVBAHA.112.300346">http://dx.doi.org/10.1161/ATVBAHA.112.300346</a> |
Public note |
http://dx.doi.org/10.1161/ATVBAHA.112.300346 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Source of classification or shelving scheme |
Other/Generic Classification Scheme |
Item type description |
Article |